MedTrace Logo

AMT-116 in Combination With Ivosidan in Patients With Lung Cancer

NCT07590531 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Conditions

  • Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

AMT-116

AMT-116 is an antibody Drug Conjugate (ADC)

DRUG

AK112

AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug

Sponsors & Collaborators

  • Multitude Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-05-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07590531 on ClinicalTrials.gov